Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population

Summary

The aim of this study is to define the role of H. pylori eradication in the prevention of gastric cancer and its precursors in the context of a population-based endoscopic screening program.

Conditions

• Gastric Cancer
• Helicobacter Pylori Infection

Interventions

DRUG

10-day bismuth-based quadruple therapy

Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days

OTHER

Placebo

Placebo for bismuth-based quadruple therapy

Sponsors & Collaborators

• International Agency for Research on Cancer

  collaborator OTHER

• Chonnam National University Hospital

  collaborator OTHER

• Chung-Ang University Hosptial, Chung-Ang University College of Medicine

  collaborator OTHER

• Pusan National University Hospital

  collaborator OTHER

• Kyungpook National University Hospital

  collaborator OTHER

• Uijeongbu St. Mary's Hospital/The Catholic University

  collaborator UNKNOWN

• Kangdong Sacred Heart Hospital

  collaborator OTHER

• Incheon St.Mary's Hospital/The Catholic University

  collaborator UNKNOWN

• SMG-SNU Boramae Medical Center

  collaborator OTHER

• Chuncheon Sacred Heart Hospital

  collaborator OTHER

• Kosin University Gospel Hospital

  collaborator OTHER

• National Cancer Center, Korea

  lead OTHER_GOV

Principal Investigators

• Il Ju Choi, M.D., Ph.D. · National Cancer Center, Korea

• Rolando Herrero, M.D.,Ph.D · International Agency for Research on Cancer

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

40 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2014-06-30

Primary Completion

2029-12-31

Completion

2029-12-31

Countries

• South Korea

Study Locations